VNDA Vanda Pharmaceuticals Inc.

14.15
+0.10  (1%)
Previous Close 14.05
Open 14.05
Price To book 4.88
Market Cap 635724479
Shares 44,927,525
Volume 100,159
Short Ratio 2.80
Av. Daily Volume 544,321

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171185033
  2. 8-K - Current report 171183429
  3. 8-K - Current report 171141740
  4. 8-K - Current report 171083665
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171002758

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due mid-2018.
Tradipitant
Gastroparesis
PK trial initiated with full enrollment due by end of 2017.
HETLIOZ (tasimelteon) - pediatric formulation
Insomnia
Approved May 26, 2016.
Fanapt
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
Insomnia
Phase 2 data due in 4Q 2017.
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 3 initiated 4Q 2016. Data due 2018.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 2 data released September 13, 2017 - primary endpoint not met. Phase 3 trial to commence 1H 2018.
Tradipitant
Atopic dermatitis

Latest News

  1. Edited Transcript of VNDA earnings conference call or presentation 7-Nov-17 9:30pm GMT
  2. Research Report Identifies Walker & Dunlop, Vanda Pharmaceuticals, Acushnet, SS&C Technologies, ManpowerGroup, and Glaukos with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  3. Vanda Pharmaceuticals Announces Participation at November 2017 Investor Conferences
  4. Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia
  5. Vanda reports 3Q loss
  6. Vanda Pharmaceuticals Reports Third Quarter 2017 Financial Results
  7. Vanda Pharmaceuticals Inc. to Host Earnings Call
  8. ETFs with exposure to Vanda Pharmaceuticals, Inc. : October 27, 2017
  9. Vanda Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017
  10. Vanda Pharmaceuticals Announces Participation at the Oppenheimer Specialty Pharma Summit Conference
  11. Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : October 10, 2017
  12. Vanda to Present Tradipitant Phase II Atopic Dermatitis Data at World Congress of Itch
  13. Vanda to Present Scientific Posters at World Sleep 2017
  14. Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
  15. These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys?
  16. Is It Too Late To Buy Vanda Pharmaceuticals Inc (VNDA)?
  17. Summit Therapeutics Stock Gets Smoked After IPO Pricing
  18. Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis